文献速递类风湿关节炎

24年间单中心类风湿关节炎患者骨质疏松及骨质疏松性骨折显著减少

Significant decrease of osteoporosis and osteoporotic fractures in rheumatoid arthritis within a period of 24 years: experiences of a single centre.
PubMed 文献 · RMD Open · 2024-08-20

队列2骨质疏松患病率、外周骨折及椎体骨折均显著低于队列1,生物制剂使用更常见而糖皮质激素使用更少;在病程超过2年的患者中,使用生物制剂者骨密度显著更高。

要点

  • 队列2骨质疏松患病率28.3%显著低于队列1的48.4%(p<0.001)。
  • 队列2骨质疏松性外周骨折11.5%及椎体骨折6.6%均显著低于队列1的21%和10.9%。
  • 病程超过2年者使用生物制剂时骨密度显著更高(p<0.001),尽管累积糖皮质激素剂量更高。

核心结论

  • 24年间类风湿关节炎患者骨质疏松及骨质疏松性骨折显著下降,该积极效应与2005至2019年间生物制剂使用更频繁相关。

主要发现

  • 队列2骨质疏松患病率28.3% vs 队列1 48.4%(p<0.001),骨质疏松性外周骨折11.5% vs 21%(p<0.001),椎体骨折6.6% vs 10.9%(p=0.011),均为队列2显著更低。
  • 队列2生物制剂治疗19.7% vs 队列1 5.0%(p<0.001),生物制剂使用显著更常见;糖皮质激素使用显著更少(p=0.005)。
  • 在病程超过2年的类风湿关节炎患者中,使用生物制剂者骨密度显著更高(p<0.001),尽管累积糖皮质激素剂量更高(p<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Rheumatoid arthritis (RA) is associated with an increased risk for osteoporosis and osteoporotic fractures. Since the treatment of RA has improved significantly in recent years, we can expect RA-associated osteoporosis to decrease with good disease control. Therefore, we conducted a retrospective study to investigate whether the frequency of osteoporosis and osteoporotic fractures has changed during 24 years in RA. METHODS: We analysed the data of 1.086 RA patients from the time of the first osteological assessment with bone mineral density (BMD) measurement and collection of osteologically important data during the years 1996 and 2019 at our clinic. According to the treatment period, the patients were divided into cohort 1 (investigation between 1996 and 2004; n=539) and cohort 2 (investigation between 2005 and 2019; n=547). The data of the two cohorts were compared, and predictors of BMD were analysed by linear regression analysis. RESULTS: Prevalence of osteoporosis (28.3% vs 48.4%; p<0.001) as well as osteoporotic peripheral fractures (11.5% vs 21%; p<0.001) and vertebral fractures (6.6% vs 10.9%; p=0.011) were significantly lower and treatment with biologicals (19.7% vs 5.0%; p<0.001) significantly more common and glucocorticoid use was significantly less common (p=0.005) in cohort 2. In RA patients with a disease duration of more than 2 years, BMD was significantly higher under treatment with biologicals (p<0.001) despite increased cumulative glucocorticoid dosages (p<0.001). CONCLUSION: Our study showed a significant decline in osteoporosis and osteoporotic fractures in RA for 24 years. This positive effect is associated with the more frequent use of biologicals in the years between 2005 and 2019.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Oelzner P, Mueller PH, Hoffmann T, et al. Significant decrease of osteoporosis and osteoporotic fractures in rheumatoid arthritis within a period of 24 years: experiences of a single centre. RMD Open. 2024. PMID: 39164051. doi:10.1136/rmdopen-2024-004564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。